Vivos Therapeutics Announces Results of Children and Tooth Decay Study

Vivos Therapeutics Announces Results of Children and Tooth Decay Study

Vivos Therapeutics has announced the results of a study done on tooth decay in pediatric patients. This peer-reviewed study demonstrated that there was a significant reduction of tooth decay in pediatric patients after undergoing treatment using the Vivos Guide. The Vivos Guide is an intraoral device that acts as a tooth positioner intended to prevent children’s teeth from shifting position.

This study evaluated the ability of the Vivos Guide to convert mouth breathing to nose breathing in children. Nose breathing rather than mouth breathing reduces the risk of decay. In the study, 20 children were divided into a control group and a treatment group. 40 children ranging from ages 4-12 were treated with the Vivos Guide, and both groups of children were given the same information on how to prevent tooth decay.

Vivos Therapeutics, which focuses on treatment modalities for patients who suffer from sleep-disordered breathing, said that this study was done by independent Vivos Clinical Advisor Toshi Hart, DDS.

“I am happy with the results of this study,” Dr Hart said in a press release from the company. “Having worked with so many children over 3 decades, I have witnessed the correlation of tooth decay in relation to mouth breathing. I am pleased that my contribution in this study helps to show how the use of the Vivos Guide intraoral device may promote nasal breathing and reduce tooth decay.”

The Vivos Guide is an FDA Class 1 registered product, and is designed to aid pediatric patients with sleep-disordered breathing.